The FDA has issued its most serious warning for Veozah, a drug used to relieve menopause symptoms, due to the risk of liver issues. The agency recommends regular blood testing for patients taking the medication.
The U.S. Food and Drug Administration ( FDA ) has issued a black-box warning for Veozah , a medication used to relieve menopause symptoms. In a new communication issued Dec. 17, the FDA advised that women taking Veozah should undergo regular blood testing to monitor for liver issues. Patients experiencing elevated liver markers should immediately stop taking the medication and consult with their doctor.
The medication works by blocking neurokinin B, a receptor involved in the brain's regulation of body temperature. Since its approval, the drug's popularity has grown steadily, with nearly 29,000 prescriptions filled in May 2024 alone, according to FDA data. The FDA's heightened warning comes after reviewing a recent case where a patient developed elevated liver markers after taking Veozah for about 40 days. To minimize risk, the FDA recommends monthly blood tests for liver markers during the first three months of Veozah treatment and follow-up tests at months six and nine. Because medication effects can vary widely due to health, genetics, and other factors, the FDA emphasized that it is difficult to predict who might develop liver issues
FDA Veozah Menopause Liver Issues Black Box Warning
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Issues Boxed Warning for Veozah Over Liver Damage RiskThe FDA has issued a Boxed Warning for Veozah, a new drug for managing hot flashes associated with menopause, due to the risk of liver damage. Patients are advised to discuss their treatment with their doctor and undergo regular liver function tests.
Read more »
FDA Issues Second Highest Risk Recall for Metal-Contaminated Bread ProductsThe FDA has issued a Class II recall for two bread products manufactured by Stuyver's Bread due to possible metal contamination. The recall affects 1,777 product cases and spans several states. Ingesting metal fragments can pose serious health risks, including lacerations, punctures, and allergic reactions.
Read more »
FDA Issues Advisories and Recall for Oysters and Manila Clams Over Norovirus ContaminationThe Food and Drug Administration (FDA) has issued advisories and a recall for oysters and Manila clams due to potential contamination with norovirus. The advisories affect oysters and clams harvested in Washington and Canada, prompting retailers and restaurants to halt sales and consumers to discard affected products. The recall specifically targets oysters sold under the names Fanny Bay, Buckley Bay, and Royal Miyagi, harvested in British Columbia.
Read more »
Vegetable Recall Update As FDA Issues Most Serious Concern LevelThe recall was issued over E. Coli fears in portions of carrots provided to 4Earth Farms of Commerce by Grimmway Farms.
Read more »
FDA Issues Recalls for Supplements Containing Undeclared Drug IngredientsThe U.S. Food & Drug Administration (FDA) has issued recalls for three supplement products due to the presence of undeclared drug ingredients. These recalls highlight the importance of consumer vigilance and the need for supplement companies to ensure the safety and accuracy of their products.
Read more »
InnovationRx: FDA Issues New Guidance For AI In Medical DevicesAlex Knapp is a senior editor covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He's written dozens of profiles of entrepreneurs across a variety of fields and done deep dives into technological trends from superconductors to space travel to pharmaceuticals.
Read more »